Observe Medical ASA · OSL:OBSRV
Observe Medical ASA — Q4 2020 Earnings Presentation
33 slides from Observe Medical ASA's earnings presentation, Feb 23, 2021
Slide 1: Observe Medical Q4 2020
OBSERVE MEDICAL Q4 2020 CEO Björn Larsson / CFO Per Arne Nygård Oslo, February 23, 2021
Slide 2: Solid medtech platform for growth
OBSERVE MEDICAL Overview Sippi® Automated and wireless connected Solid medtech platform for growth digital urine meter for ICUs and wards
Slide 3: The 2020 journey – key initiatives
OBSERVE MEDICAL Overview The 2020 journey – key initiatives Solid financial basis: Strengthened sales capabilities: Rights issue of NOK Sylak acquisition 45 million in Q4 2020 Solid medtech platform for growth Distributor New scientific agreement in Italy evidence published Sippi® Automated and wire
Slide 4: Solid medtech platform for growth
OBSERVE MEDICAL Overview Solid medtech platform for growth Observe Medical Sippi® Nordic Sales Operations Automated and wireless connected digital urine Highly competent sales team and medtech product meter for ICUs and wards portfolio enabling customer access for Sippi® Strong market opportunity –
Slide 5: Slide 5
Slide 6: Hourly urine monitoring is one of the last manual monitoring procedures
Hourly urine monitoring of patients is one of the last remaining manual monitoring procedures in the ICU with significant clinical implications Risk of infections Inaccurate patient data for clinical decisions Time-consuming for staff and compromised ergonomics - reducing clinical capacity
Slide 7: Sippi addresses the clinical challenges
SIPPI® Sippi® addresses the clinical challenges Only automated, digital urine meter with wireless data transfer (Sipplink®) to the hospital patient data management system and which detects (Sippsense®) and hinders (Sippcoat®) bacterial biofilm formation – that can lead to urinary infections. Hinderi
Slide 8: Recent doctoral dissertation further demonstrates clinical benefits of Sippi
SIPPI® Recent doctoral dissertation further demonstrates clinical benefits of Sippi® “The AU was non-inferior to the MU regarding precision, and significantly better than the MU in terms of bias, temporal deviation and staff opinion.” "...the higher measurement resolution that may be obtained with t
Slide 9: Significant market opportunity for Sippi remains
SIPPI® Significant market opportunity for Sippi® remains CURRENT MARKET POTENTIAL ICU CAPABILITIES VOLUME GROWTH MARKET VALUE GROWTH Sippi® market opportunity ~0.5M +30M +20-30% +100% Sippi® base Sippi® disposable Market volume units units/bags per year Stepwise go-to-market plan execution Global la
Slide 10: Good progress in accelerating clinical use
SIPPI® Good progress in accelerating clinical use – new hospitals and clinics added in Q4 2020 and Q1 2021 NORDICS Nya Karolinska hospital, Sweden Cardiothoracic ICU unit • Resumed clinical implementation Q1 ENABLER FOR CONTINUED 2021 after pause during 2020 due to ACCELERATION: Covid-19 Strengthene
Slide 11: Sippi market access through strong sales teams and synergistic portfolio
SYLAK ACQUISITION Sippi® market access through strong sales teams and synergistic product portfolio – both with Nordics direct sales and with distributors Observe Medical – Nordic Sales Operations Strengthened access to Sippi® target customers Urine measurement including Sippi® Direct sales Nordics
Slide 12: Financial Review
FINANCIAL REVIEW CFO Per Arne Nygård
Slide 13: Financial review comments
FINANCIAL REVIEW Financial review comments Acquisition of Sylak AB Contingent consideration Product groups / Earn-out agreement Included in Observe Medical Group Urine measurement Increased liability due to: financial statement from 1 November 2020 • Increased long-term revenue forecast compared to
Slide 14: Revenue and gross results Q4 2020
FINANCIAL REVIEW Revenue and gross results Q4 2020 Revenues Q4 2020 Revenue and gross results Revenue breakdown by category TNOK TNOK • Total revenues at TNOK 2 920 2 920 • Revenues at TNOK 2 880 in November and December from new acquired product portfolio Gross • Strong sales growth in new margin:
Slide 15: Revenue and gross results FY 2020
FINANCIAL REVIEW Revenue and gross results FY 2020 Revenues FY 2020 Revenue and gross results Revenue breakdown by category TNOK TNOK • Total revenues at TNOK 2 961 2 961 Gross result FY 2020 Gross margin: 986 • Gross result at TNOK 986 in 219 33.3% 447 2020 • Gross margin at 33.3% 1 975 2295 177 Ur
Slide 16: Key figures Profit and loss statement
FINANCIAL REVIEW Key figures Profit and loss statement Operating expenses Q4 2020 Amounts in NOK thousand (excl. earnings per share) Q4 2020 Q4 2019 FY 2020 FY 2019 • Increased headcount mainly due to acquisition of Sylak Gross result 1 071 70 986 -460 Operating expenses 10 569 3 631 25 910 11 041 •
Slide 17: Key figures - Statement of Financial Position
FINANCIAL REVIEW Key figures - Statement of Financial Position (Amounts in TNOK) At 31 December 2020 At 31 December 2019 ASSETS Assets Non-current assets Goodwill 36 268 30 333 • Increased Goodwill due to Intangible assets and tangible assets 21 668 21 336 acquisition of Sylak AB and Total non-curre
Slide 18: Key Figures Cash Flow Statement fourth quarter 2020
FINANCIAL REVIEW Key Figures Cash Flow Statement fourth quarter 2020 • Negative cash flow from operations due to the result in the period 31,430 • Cash flow used in investing -4,939 activities is mainly due to net -7,511 cash effect of the Sylak acquisition at TNOK 6,838 and investment in tangible a
Slide 19: Summary and Outlook
SUMMARY AND OUTLOOK CEO Björn Larsson
Slide 20: Summary & Outlook
OBSERVE MEDICAL Summary & Outlook Summary Outlook Continued rollout of Sippi® systems in clinical use Continued focus on the Nordics and Europe Sippi® in clinical use in ICU unit at major hospital in Northern Italy Continuous roll-out of Sippi® systems for clinical use Karolinska Nya Sjukhuset resum
Slide 21: Q&A
Q&A
Slide 22: Thank you!
Thank you!
Slide 23: Finance calendar
OBSERVE MEDICAL Finance calendar 20 August 12 May Presentation of Presentation of Q2 and first half Q1 2021 year 2021 30 April 21 May 3 November Publication of Annual General Presentation of Annual report Meeting Q3 2021 2020
Slide 24: Appendix
Appendix
Slide 25: Management team
OBSERVE MEDICAL Experienced management team and board Management team Björn Larsson Per Arne Nygård Mikael Löfgren Anders Nachtweij Chief executive officer Chief financial officer CTO/COO Sales Director Board of directors Terje Bakken Kristin Nyberg Kathrine Gamborg Andreassen Thomas Grünfeld Chairm
Slide 26: Condensed Consolidated Statement of Comprehensive Income
(UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2020) Condensed Consolidated Statement of Comprehensive Income (Amounts in NOK) Q4 2020 Q4 2019 FY 2020 FY 2019 Operating revenues 2 920 001 94 389 2 961 334 176 650 Cost of materials 1 848 654 24 431 1 975 121 636 781 Gross result 1 071 348 69 958 986 212
Slide 27: Condensed Consolidated Statement of Financial Position
(UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2020) Condensed Consolidated Statement of Financial Position (Amounts in NOK) At 31 December 2020 At 31 December 2019 ASSETS Non-current assets Goodwill 36 268 318 30 333 459 Intangible assets 20 965 076 20 997 241 Tangible assets 702 757 339 069 Total non
Slide 28: Condensed Consolidated Statement of Financial Positions
(UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2020) Condensed Consolidated Statement of Financial Positions (Amounts in NOK) At 31 December 2020 At 31 December 2019 EQUITY AND LIABILITIES Total equity 20 349 125 14 541 734 Non-current liabilities Non-current lease liabilities 260 356 77 945 Contingent
Slide 29: Cash Flow Statement
(UNAUDITED FOR THE PERIOD ENDED 31 DECEMBER 2020) Cash Flow Statement (Amounts in NOK) Q4 2020 Q4 2019 FY 2020 FY 2019 Cash flow from operating activities Result before tax -20 445 731 -4 523 613 -36 868 470 -16 917 301 Depreciation and impairment 779 059 1 083 182 3 163 304 4 285 200 Change in net
Slide 30: Top 20 Shareholders
AS OF FEBRUARY 19, 2021 Top 20 Shareholders Rank Name Number of shares % of top 20 % of total Country 1 NAVAMEDIC ASA 4 222 727 25,40 % 21,54 % Norway 2 INGERØ REITEN INV. COMPANY AS 3 939 394 23,69 % 20,09 % Norway 3 RO, LARS 1 500 000 9,02 % 7,65 % Norway 4 UBS Switzerland AG 1 417 522 8,53 % 7,23
Slide 31: Definitions of Alternative Performance Measures (APM)
OBSERVE MEDICAL Definitions of Alternative Performance Measures (APM) The APMs are regularly reviewed by management and their aim is to enhance stakeholders’ understanding of the company’s performance. APMs presented may be determined or calculated differently by other companies. Gross result: Opera
Slide 32: Copyright and Disclaimer
OBSERVE MEDICAL Copyright and Disclaimer Copyright Disclaimer reliability or completeness of the Copyright of all published material This Presentation includes and is based, Presentation, and neither Observe Medical including photographs, drawings inter alia, on forward-looking information ASA nor a
Slide 33: oKeonserve
oKeonserve Taaexe |(er=l|